<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05797935</url>
  </required_header>
  <id_info>
    <org_study_id>9805821254</org_study_id>
    <nct_id>NCT05797935</nct_id>
  </id_info>
  <brief_title>Evaluation of Changes in Pancreatic Fat Content Using Advanced MR Sequences in Diabetics on Dapagliflozin Therapy</brief_title>
  <official_title>Evaluation of Changes in Pancreatic Fat Content Using Advanced MR Sequences in Diabetics on Dapagliflozin Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Postgraduate Institute of Medical Education and Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Postgraduate Institute of Medical Education and Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aimed to assess changes in pancreatic fat content in people with diabetes on&#xD;
      dapagliflozin (SGLT2 inhibitor) and beta cell function.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study assessed and estimated the difference in pancreatic fat content in the patients of&#xD;
      Type 2 Diabetes Mellitus at baseline and after taking dapagliflozin for 24 weeks.&#xD;
&#xD;
      The investigators even estimated the correlation between two advanced MR techniques commonly&#xD;
      used for quantification of pancreatic fat (PDFF and MR Spectroscopy)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 1, 2021</start_date>
  <completion_date type="Actual">December 31, 2022</completion_date>
  <primary_completion_date type="Actual">December 20, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomised Control Trial</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Investigator)</masking>
    <masking_description>Single blind study</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>To assess and estimate the difference in pancreatic fat content in the patients of Type 2 Diabetes Mellitus at baseline and after taking dapagliflozin for 24 weeks</measure>
    <time_frame>24 weeks</time_frame>
    <description>The pancreatic fat percentage will be measured by MRI sequences at baseline and at 24 weeks and a change will be compared</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To estimate the correlation between two advanced MR techniques commonly used for quantification of pancreatic fat(PDFF and MR Spectroscopy)</measure>
    <time_frame>24 weeks</time_frame>
    <description>The pancreatic fat percentage will be measured by MRI sequences at baseline and at 24 weeks and a correlation will be assessed</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Pancreatic Lipomatosis</condition>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Only the standard drugs for type 2 diabetes were given. Dapagliflozin was not given in this group.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dapagliflozin group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The patients were given standard drugs for type 2 diabetes and Dapagliflozin.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin 10mg Tab</intervention_name>
    <description>Dapagliflozin was given at a dose of 10 mg/day in one group and its effect was observed on the pancreatic fat content</description>
    <arm_group_label>Dapagliflozin group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 18 years,&#xD;
&#xD;
          2. Hba1c 7-11%,&#xD;
&#xD;
          3. Renal function (MDRD) &gt; 30 ml/min, on glucose-lowering therapy {metformin,&#xD;
             sulfonylureas, glinides, dipeptidyl peptidase-4 (DPP-4) inhibitors, or basal insulin}&#xD;
             at a stable dose for at least 3 months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Uncontrolled hyperglycemia at screening (fasting blood glucose FBG ≥ 240 mg/dL).&#xD;
&#xD;
          2. Diabetes other than type 2 diabetes&#xD;
&#xD;
          3. Age younger than 18 years.&#xD;
&#xD;
          4. Pregnant patients or lactating.&#xD;
&#xD;
          5. Patients who refuse to give consent to be enrolled in the study.&#xD;
&#xD;
          6. Any contraindication to magnetic resonance imaging.&#xD;
&#xD;
          7. More than 5% total body weight loss within the last month.&#xD;
&#xD;
          8. Patients with moderate or severe renal impairment&#xD;
&#xD;
          9. Any contraindication to SGLT2i&#xD;
&#xD;
         10. Prior SGLT2i within the past 3 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Deptt of Endocrinology</name>
      <address>
        <city>Chandigarh</city>
        <zip>160012</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>April 2023</verification_date>
  <study_first_submitted>March 22, 2023</study_first_submitted>
  <study_first_submitted_qc>March 22, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">April 4, 2023</study_first_posted>
  <last_update_submitted>April 6, 2023</last_update_submitted>
  <last_update_submitted_qc>April 6, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Postgraduate Institute of Medical Education and Research</investigator_affiliation>
    <investigator_full_name>Ashu Rastogi</investigator_full_name>
    <investigator_title>Associate professor, Department of endocrinology and metabolism , PGIMER chandigarh</investigator_title>
  </responsible_party>
  <keyword>Dapagliflozin</keyword>
  <keyword>Pancreatic fat</keyword>
  <keyword>MRI</keyword>
  <keyword>Diabetes</keyword>
  <keyword>MRS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lipomatosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dapagliflozin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

